Go to Liminal BioSciences Q3 Results Conference Call on Friday, Nov 13, 2020 8:30 AM ESTView Now
Other content in this Stream
Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.
LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.
LMNL announced the presentation of two scientific posters highlighting potential activity of intravenous Ryplazim® (plasminogen) on infertility and acute airway obstruction in patients with C-PLGD.